Updated with four more trademark filings.
No retatrutide brand name yet, but Lilly filed twenty new trademarks in a month and nineteen of them are built on reta or ret. Here is what that tells you, and what it does not.
Retatrutide status, checked September 4, 2026: FDA approved: No · FDA filing: planned Q1 2027 · Retatrutide brand name: not announced · US price: not announced, though I have worked out what I expect it to cost.
Disclosure: I take Zepbound, a Lilly drug, and I own Eli Lilly stock, the only pharmaceutical stock I hold.
I write about this molecule’s grey market and the lawsuits around it often, so when Lilly filed a batch of new trademarks on September 2, I pulled the whole file out of the USPTO database.
Does retatrutide have a brand name yet?
No. Lilly has not announced one. It is still called retatrutide, its nonproprietary scientific name, and LY3437943, the in-house development code.
What changed is the filing record. The twenty applications went in on August 4, August 5 and September 2. Before August 4 the company owned exactly one live mark containing reta, KORPRETA, filed back in 2023.
Update, October 8, 2026: Lilly filed four more names with the USPTO on October 7: RETAVERA, RETAVERRA, ZOUNRETA and VOUNRETA. All four are in Class 005 and went in on the same day, so they look like more candidates being cleared. Lilly has still not announced a brand name.
The full pull covers seventeen new applications; WYNNRET, YEZRET and YIELM are missing from the detailed pull. All seventeen are in Class 005, the pharmaceutical class, and are intent-to-use filings, the kind you make for a name you have not sold anything under yet. As of September 4, every one I pulled was still marked as awaiting assignment to an examining attorney, so examination has not started on any of them.
Get the next one in your inbox
I cover the latest GLP-1 trials and access changes weekly. Free, no spam, unsubscribe whenever.
Which trademarks could be the retatrutide brand name?
The applications themselves will not tell you. In the seventeen full records, Lilly describes the goods as either “pharmaceutical preparations; vaccines for human use” or a list of roughly forty-five conditions running from alcohol use disorder to vision loss. Both are boilerplate, and neither says retatrutide anywhere. One of these names turning up in Class 044, the medical-services class, with an indication written next to it would narrow the field. That is the filing worth watching for.
One thing does separate them. With Zepbound, Lilly bought the matching .com the day before it filed the trademark: zepbound.com was registered on April 13, 2022, and the application went in the next day. The registrant name is withheld on the new domains, so what follows is a match on registrar and nameservers, the servers that answer for a domain, not a name on a record. Eleven of the nineteen sit at GoDaddy Corporate Domains on the same two nameservers as retatrutide.com, which Lilly has held since 2022. The earliest three, vynnreta.com, vymreta.com and wynnret.com, were registered on April 21, three and a half months before the first application. The other eight are on consumer registrars and show no sign of being Lilly’s.
| Mark | Filed | Domain at Lilly’s registrar |
|---|---|---|
| VYNRETA, VYNNRETA | Aug 4 | Yes (Apr 21 and Jul 31) |
| VYMRETA, VYMMRETA | Aug 4 | Yes (Apr 21 and Jul 31) |
| RETAHNOVA, RETAHVERA, VERAHRETA | Aug 4 | Yes (Jul 31) |
| HIRETA | Aug 4 | No, taken since 2016 |
| YEZRETA, YEZRET, YEZZRETA | Aug 5 | No, taken hours after filing |
| VOYRETA, ONERETA, REALLRETA, WYNNRET | Sep 2 | Yes (Apr 21 to Sep 1) |
| ONRETA, REALRETA, TRURETA, RETANOVA | Sep 2 | No, all taken earlier |
That puts the vyn and vym pairs, VYNRETA and VYNNRETA, VYMRETA and VYMMRETA, in the group carrying Lilly’s fingerprint at the registrar as well as at the USPTO. The yez group is the one that breaks the pattern. YEZRETA, YEZRET and YEZZRETA were all registered on the evening of August 5, the day Lilly filed them, within two minutes of each other, through a Hong Kong registrar, and they point at a domain marketplace.
Lilly filed a third EU extension on September 16: RETAHVERA, EU application 019423157, listing the same broad Class 005 goods plus obesity, obstructive sleep apnea, osteoarthritis, diabetes, metabolic disease and weight management by name. A EUIPO filing is a stronger tell than a domain match, since it costs real money in a second jurisdiction, and it puts RETAHVERA alongside YEZRETA and YEZZRETA, both filed in the EU on August 6, as the only U.S. candidates Lilly has also filed in Europe. VYNRETA, VYNNRETA, VYMRETA, VYMMRETA, VERAHRETA and RETAHNOVA, the names carrying Lilly’s own domain fingerprint, have no matching EU filing. The day before, on September 15, Lilly put out a major release on upcoming EASD data covering Foundayo, retatrutide and eloraTZP; it names Foundayo but still calls the triple agonist retatrutide throughout.
Lilly sells tirzepatide under two names, Mounjaro for diabetes and Zepbound for weight loss. Retatrutide is in Phase 3 trials for seven conditions, and Lilly’s first filing will cover three, so more than one of these names could end up on a label.
What happened the last time Lilly named a drug like this
On a single day in April 2020, Lilly filed six trademarks built on zep, the syllable in the middle of tirzepatide: ZEPJURNI, RYTEZEP, TAYZEPTRO, YAZEPSA, APMYZEP and JETZEPICA. All six are dead. Two more, ZEPLIFY and IZEPLIFY, followed in February 2021 and also died. The name Lilly actually used, Zepbound, was filed on its own in April 2022, and the drug was approved under it in November 2023.
Mounjaro followed a similar sequence. That mark was filed in November 2019, two and a half years before approval, and the near-miss spellings that protect it were not filed until December 2021, after the decision was made.
So I would not read this batch as a decision. Filing a batch of near-identical names in one go looks like clearing candidates. In my pull of Lilly’s zep marks, Zepbound was the only one filed on April 14, 2022, while every mark in this batch shared its filing day with others. The FDA also reviews the proposed name separately from the drug and can reject it outright, which is a second reason a filing is not a decision.
Who makes retatrutide?
Eli Lilly, the same company behind Mounjaro, Zepbound and Trulicity. Retatrutide is a triple agonist, meaning it acts on three gut-hormone receptors (GLP-1, GIP and glucagon) instead of the one or two that older drugs in this class target. Lilly has reported positive results from five Phase 3 trials and says the FDA filing it plans for the first quarter of 2027 will cover obesity, obstructive sleep apnea and knee osteoarthritis pain. I went through how it compares with Zepbound separately; it looks like a real step up.
Are the reta brands already on sale Lilly’s?
Trureta is one of the names Lilly filed on September 2. The domain has been registered since July 25 by somebody behind a privacy service, and it forwards to a Shopify store selling “40 mg prefilled Retatrutide pens for laboratory research use.” Lilly filed for that trademark five weeks after the store took the address.
Retanova, filed the same day, has the same problem. A metabolism-support supplement called Retanova, made by Verde Ads FZ-LLC and sold into the EU through a Dublin distributor, has been running at getretanova.com since the domain was registered on August 5, four weeks before Lilly’s filing.
Supplement companies are filing reta names too: RETASLIM, RETABOLIC and RETA MD, none of them Lilly’s and none of them retatrutide. I have written before about what is actually in those vials and why none of it is legal to sell, and a brand-sounding name is one more thing sellers use to look official.
Lilly’s last three GLP-1 names, Mounjaro, Zepbound and Foundayo, were all public on the day the FDA approved them. Lilly says it will file retatrutide in early 2027. My forecast is that a decision, or a name, will not come before the second half of 2027, and it could slip. I ran the same query against Novo Nordisk, which has eleven invented names on file and has not announced one for CagriSema either: does CagriSema have a brand name yet. I track every drug in this class on my GLP-1 pipeline tracker and check Lilly’s trademark filings daily, so this page will change the day a name is announced. Until then, a specific name attached to retatrutide is somebody’s guess or somebody’s domain investment, not Lilly’s decision.